Motif Bio PLC (LON:MTFB)‘s stock had its “speculative buy” rating restated by equities research analysts at Beaufort Securities in a research note issued on Monday.

Separately, Northland Securities reaffirmed a “buy” rating and set a GBX 140 ($1.75) price target on shares of Motif Bio PLC in a report on Tuesday, August 9th.

Shares of Motif Bio PLC (LON:MTFB) opened at 23.75 on Monday. Motif Bio PLC has a 52 week low of GBX 23.25 and a 52 week high of GBX 68.25. The stock has a 50 day moving average price of GBX 42.49 and a 200-day moving average price of GBX 47.32. The stock’s market cap is GBX 25.79 million.

COPYRIGHT VIOLATION WARNING: “Beaufort Securities Reiterates Speculative Buy Rating for Motif Bio PLC (MTFB)” was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The correct version of this article can be viewed at

Motif Bio PLC Company Profile

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.